Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025

Castle Biosciences, Inc. (NASDAQ:CSTL) has announced new data to be presented at ASCO 2025 showing that its DecisionDx-Melanoma test is linked to a 32% reduction in mortality risk for patients with cutaneous melanoma compared to those who were untested. The findings come from the largest real-world study of gene expression profile testing in melanoma, analyzing over 13,500 patients in collaboration with the National Cancer Institute’s SEER Program Registries.

A doctor using a microscope in a lab, conducting research on cancer treatments.

Castle Biosciences, Inc. (NASDAQ:CSTL)’s Dx-Melanoma test, which evaluates a 31-gene expression profile, offers significant, independent risk stratification beyond traditional AJCC staging, helping clinicians make more precise, personalized treatment decisions.

According to lead author Dr. Merve Hasanov, the test enables more accurate mortality risk predictions based on a patient’s unique tumor biology, allowing for better-tailored care.

These results further affirm the test’s association with improved patient survival and its potential to guide risk-aligned management strategies. DecisionDx-Melanoma has been ordered more than 200,000 times and is supported by over 50 peer-reviewed studies, underscoring its growing role in melanoma care and its impact on patient outcomes.

While we acknowledge the potential of CSTL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than CSTL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.